About the job
Avalyn Pharma is an innovative biopharmaceutical organization dedicated to developing advanced inhaled therapies aimed at treating rare respiratory diseases, including pulmonary fibrosis and various interstitial lung diseases (ILD). Pulmonary fibrosis leads to lung tissue scarring, diminished lung functionality, and a decline in patients' quality of life, ultimately increasing mortality rates. While existing treatment options can slow disease progression, they often come with significant toxic side effects that limit their application. Avalyn is focused on creating a pipeline of novel inhaled formulations designed to minimize systemic exposure and deliver medication directly to the affected areas. Our leading candidate, AP01, is an optimized inhaled form of pirfenidone, currently being evaluated in the ongoing MIST Phase 2b Study targeting progressive pulmonary fibrosis (PPF). Additionally, we have initiated a Phase 2 study for our second program, AP02, an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis (IPF). For further details, please visit our website at avalynpharma.com and follow us on LinkedIn.
Position Summary:
The Director of Biostatistics will provide both strategic vision and practical leadership for statistical activities across our clinical development programs. This role is essential in ensuring that the design, analysis, and interpretation of clinical trials align with regulatory requirements and support high-quality submissions. The Director will collaborate closely with Clinical Development, Clinical Operations, Data Management, Regulatory Affairs, and Medical Affairs, while also building scalable biostatistical capabilities suited for a rapidly growing organization.